TransCelerate BioPharma Launches the Shared Investigator Platform to Revolutionize Communications between Sites and Sponsors

Platform Results from a Game-Changing Collaborative Effort Among Leading Biopharmaceutical and Technology Organizations

PHILADELPHIA--()--TransCelerate BioPharma Inc. today announced the launch of the Shared Investigator Platform (SIP), a technology that will allow clinical trial sites to streamline investigative site information, and establish a central access point for interaction between the site and multiple clinical trial sponsors.

“The development of the Shared Investigator Platform was one of TransCelerate's founding initiatives aimed at reducing investigative site burden. The SIP and the supportive Investigator Registry combined should dramatically decrease the administrative burden placed on investigator sites and improve sponsor efficiencies.”

The unique design and development of the SIP was made possible through important partnerships with several key stakeholders. To ensure the investigator site perspective was included in the design of the system, participating TransCelerate Member Companies collaborated with Investigators through a Site Advocacy Group provided through a partnership with the Society for Clinical Research Sites (SCRS). The interface for the delivery of content and services to sites was developed by Cognizant, the overall system integrator and service provider who was selected to design, build and host the SIP. Cognizant incorporated capabilities by CA Technologies, DrugDev, Exostar, LifeRay and SumTotal each who played a critical role in bringing the innovative vision of the TransCelerate Member Companies to life.

Clinical research sites often have to use written documents, as well as multiple portals or applications requiring separate login accounts to perform clinical trial responsibilities for each sponsor with whom they work. As a result, communication for sites who work with multiple sponsors and across multiple studies has been cumbersome and complex. Moreover, the development and maintenance of individual sponsor portals has made operations unnecessarily costly and time-consuming.

Shared Investigator Platform Initiative Leader Jackie Kent, and Eli Lilly's Senior Director, Product Delivery Supply Planning and Systems, states, "The SIP will help us, as an industry, solve operational R&D challenges common to trial sites and sponsors. With SIP, sponsors and sites will benefit from improvements in study start up or reduction in duplicative work."

Ms. Kent goes on to note, "SIP benefits the patient by reducing the amount of time investigators dedicate to onerous administrative tasks, elevating the focus on the patient experience - a critical element to a trial's overall success and a key strategic priority for TransCelerate. Our ultimate goal at TransCelerate is to ensure that medicines are delivered to patients quickly and safely, and the SIP plays a pivotal role in realizing that."

The Shared Investigator Platform is closely connected to TransCelerate's Investigator Registry (IR) Initiative, a shared repository of investigator details. The IR links together profiles from the Shared Investigator Platform with TransCelerate Member Companies' clinical trial management systems, the DrugDev investigator network, public data and other third party sources using the universal identifier, known as the DrugDev Golden Number. The aim of the TransCelerate IR is to provide an evidence-driven approach for accelerating the identification and recruitment of qualified investigators, also providing participating TransCelerate Member Companies with a mechanism to prevent duplication of site qualification activities or generation of investigator documents.

TransCelerate's CEO, Dalvir Gill, PhD, states, "The development of the Shared Investigator Platform was one of TransCelerate's founding initiatives aimed at reducing investigative site burden. The SIP and the supportive Investigator Registry combined should dramatically decrease the administrative burden placed on investigator sites and improve sponsor efficiencies." Several TransCelerate Member Companies have announced plans to adopt SIP and IR in the near term, and the clear benefits from SIP and IR will lead others to adopt future releases in 2016 and beyond. This release marks just the beginning for the Shared Investigator Platform. Future releases of the platform will add more functions and capabilities to further promote efficiency for investigator sites conducting clinical studies.

What Does SIP Go-Live Mean For Research Sites?

The SIP will facilitate and simplify interaction between investigators and multiple clinical trial sponsors. With the SIP, sites will experience:

  • Increased efficiency and reduced administrative burden in clinical trial planning & conduct
  • Streamlined interactions, and consistent data & processes with participating SIP Sponsors
  • Reduction of data entry requirements – the ability to enter data once, and have that data re-used across SIP Studies and Sponsors

With SIP, sites can maintain more meaningful collaborations with Sponsors and investigators spend more time on what matters most - their patients.

To learn more about the Shared Investigator Platform visit: http://www.transceleratebiopharmainc.com/initiatives/shared-investigator-platform/

Also, watch our video for a brief overview on SIP here: http://www.transceleratebiopharmainc.com/videos/whatissip/

About TransCelerate BioPharma Inc.

TransCelerate BioPharma Inc. is a non-profit organization dedicated to improving the health of people around the world by accelerating and enhancing the research and development (R&D) of innovative new therapies. The organization's mission is to collaborate across the global biopharmaceutical R&D community to identify, prioritize, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines. TransCelerate evolved from conversations at various forums for executive R&D leadership to discuss current issues facing the industry, and examine solutions for addressing common challenges. The founding member companies are AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, the Roche Group, and Sanofi. Additional members that have joined since the inception of TransCelerate include Allergan, Inc., Amgen, Astellas Pharma Inc., EMD Serono, Inc. (a subsidiary of Merck KGaA, Darmstadt, Germany), Medgenics, Inc., Merck & Co., Inc., Novo Nordisk, Shionogi & Co., Ltd. and UCB.

Membership in TransCelerate is open to pharmaceutical and biotechnology companies with Research & Development operations. Executive offices are located in Philadelphia, PA. For more information, please visit http://www.transceleratebiopharmainc.com.

Follow us on Twitter: https://twitter.com/transcelerate

Reach us on LinkedIn: www.linkedin.com/company/transcelerate-biopharma-inc-

Contacts

Media:
Bliss Integrated Communication
Vicky Aguiar, 212-584-5470
Vicky@blissintegrated.com

Recent Stories

RSS feed for TransCelerate BioPharma Inc.